Quick Answer
Indivior Pharmaceuticals, Inc. reported Cash and Equivalents of $195.00 million for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $195.00M | -38.9% |
| 2024 | $319.00M | +0.9% |
| 2023 | $316.00M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $445.00M | — | -12.7% |
| June 30, 2025 | $510.00M | — | +37.1% |
| March 31, 2025 | $372.00M | — | +16.6% |
| December 31, 2024 | $319.00M | — | — |
- Indivior Pharmaceuticals, Inc. showed a decrease of -38.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Indivior Pharmaceuticals, Inc.’s cash and equivalents has declined by 38.3% (from $316.00 million to $195.00 million).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: